
Opinion|Videos|June 4, 2024
Biomarker Testing in Early-Stage NSCLC
Medical experts recommend that EGFR, ALK, and PD-L1 testing be performed as reflex tests for patients with early-stage non-small cell lung cancer to inform personalized treatment strategies.
Advertisement
Episodes in this series

- What do available data show regarding the impact of concurrent testing on 1L therapy in advanced NSCLC? (Brief high-level overview only)
- Please comment on turnaround time for results, time to 1L treatment.
Advertisement
Related to this article

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC
5


